Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 70

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 70
---
(1) Mr. Murray was designated an executive officer effective April 24, 2024. (2) Mr. Brown resigned from his role of Executive Vice President, Chief General Counsel effective November 26, 2024 and continued as an employee until March 24, 2025 to support the transition of our new Chief General Counsel. I. 2024 Compensation Program Overview and Factors Tha t Influenced 2024 Named Executive Officers’ Compensation Executive Summary 2024 was another transformative and important year for the Company. We met or exceeded a majority of our corporate goals for 2024, including the conversion of our accelerated approval for Elevidys for ambulatory patients who are at least 4 years of age to traditional approval, and were granted accelerated approval for Elevidys for non-ambulatory patients. More specifically, and to highlight some of our additional achievements in 2024: Elevidys • Expanded Label. In June 2024, the FDA expanded the label of Elevidys (delandistrogene moxeparvovec-rokl), to individuals with Duchenne who are at least 4 years of age, as well as granted accelerated approval for the treatment of non-ambulatory Duchenne patients. • Additional Data. In early October 2024, efficacy and safety results from Part 1 of Study 9001-301 (EMBARK) were published in Nature Medicine. At the 2024 World Muscle Society Congress, we presented safety and efficacy data from various SRP-9001 trials, including skeletal muscle MRI data from EMBARK, cardiac MRI data from EMBARK and five-year functional results from Study SRP-9001-101. Financial Performance • We greatly exceeded our 2024 full-year guidance. Our financial results are briefly described below and discussed in our Annual Report on Form 10-K filed with the SEC: o Elevidys Revenue ▪ Fourth quarter 2024: approximately $384 million

<div align='center'>44</div>

Full-year 2024: approximately $821 million

PMO Net Product Revenue

Fourth quarter 2024: approximately $254 million

Full-year 2024: approximately $967 million

Total Net Product Revenue (PMO Products and Elevidys)

Fourth quarter 2024: approximately $638 million

Full-year 2024: approximately $1.79 billion

This represents a 56% increase over full-year 2023, excluding collaboration and other revenue from Roche’s ex-U